On Demand Webinar

With an estimated 90% of oncology drugs failing clinical trials, there is a critical need for a more robust approach to preclinical and translational studies in immuno-oncology research.

Advanced approaches to immuno-oncology research are being galvanized with new humanized mouse models and 3D co-culture techniques to better understand therapeutic intervention. However, understanding the best model is critical to building successful IO studies with interpretable readouts.

In this webinar, we will provide insights into immuno-oncology ex vivo assays and in vivo models to help improve the accuracy of preclinical studies.

Meet Our Presenter:

Mara Gilardi, PhD, Immuno-oncology Subject Matter Expert, Champions Oncology

At the helm of Champions Oncology's immunology division, Mara synthesizes over 3 years of dedicated effort in translating cutting-edge research into clinical applications. Her core competencies include in-depth tumor microenvironment profiling with multiomics data, the development of ex vivo 2D-3D models and in vivo orthotopic models in immunodeficient and humanized animals, IHC and multiplex analysis and biomarker identification, which are instrumental in advancing our understanding and treatment of cancer.

Her mission is to bridge the gap between laboratory discoveries and patient care, driven by the ethical application of science and a commitment to improving clinical outcomes. Collaborating with industry leaders and our commercial and scientific teams, I am focused on fostering innovative R&D and marketing strategies while contributing to developing next-generation therapies.